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cTo the Editor: High platelet reactivity (HPR) on clopidogrel has
been found to be associated with a significantly higher incidence of
ischemic recurrence in patients with acute coronary syndromes
(ACS) undergoing percutaneous coronary intervention with stent
implantation (1–3). We have documented that HPR in the acute
phase of ACS is associated with a risk of cardiovascular death and
major adverse cardiac events at a 2-year follow-up (4), allowing us
to identify high-risk patients for whom more aggressive antiplate-
let therapy might be beneficial.
Based on these findings, our department has adopted the
strategy to routinely measure the entity of platelet inhibition in the
acute phase of patients admitted for ACS by light transmission
aggregometry (LTA).
Platelet reactivity assessment is made by LTA (APACT 4,
Helena Laboratories, Milan, Italy) using 10 mol/l adenosine
iphosphate (ADP), 1 mmol/l arachidonic acid (AA), and 2 g/ml
collagen as agonists. Blood samples anticoagulated with 0.109
mol/l sodium citrate (ratio 9:1) were obtained within 48 h from
clopidogrel loading. HPR by ADP is defined as the presence of 10
mol/l ADP LTA 70% (5).
Since October 2011, our pharmacy delivers clopidogrel base
nstead of clopidogrel hydrogen sulfate to the departments of our
niversity Hospital (AOUCareggi, Florence, Italy). Clopidogrel base
s a generic preparation not identical to the initial clopidogrel
ydrogen sulfate.
We compared laboratory data for the period October 2011
hrough March 2012 (on clopidogrel base [A]) with data obtained
or the same period of the previous year (i.e., October 2010
hrough March 2011) (on clopidogrel hydrogen sulfate [B]).
We included 1,579 patients (1,111 men and 468 women,
1.7  11.7 years of age) with ACS (765 ST-segment elevation
yocardial infarction [STEMI]/814 non–ST-segment elevation
yocardial infarction [NSTEMI]).
No significant differences were found in age (A: 72  12 years
s. B: 71  12 years, p  0.108), sex (male/female: A, 521/220 vs.
, 590 of 248; p  0.999) and prevalence of classic cardiovascular
isk factors between the 2 groups of patients (diabetes: A, 21.9%
s. B, 22.9%; p  0.673; hypertension: A, 68.8% vs. B, 68%; p 
.745; smoking: A, 50.3% vs. B, 49.5%; p  0.762; dyslipidemia:
, 39.1% vs. B, 39.3%; p  0.959). In addition, a similar
ercentage of patients was admitted for STEMI (A, 363/741 vs. B,
02/436; p  0.724).
From our laboratory dataset, we have observed a significantly
igher percentage of patients with HPR by ADP during the
dministration of clopidogrel base with respect to clopidogrel
ydrogen sulfate (314 of 741, 42.4% vs. 213 of 838, 25.4%; p 
.0001) (Fig. 1). LTA by AA did not significantly differ
etween the 2 periods (A, 18  7% vs. B, 17  9%; p  0.715).
TA by collagen was significantly higher during the adminis-ration of clopidogrel base (A, 36.7  15.2% vs. B, 33.5 
6.6%; p  0.001.
After adjustment for age, sex, classic cardiovascular risk factors,
nd STEMI/NSTEMI, the prevalence of HPR by ADP remained
ignificantly higher in the clopidogrel base group compared with
he clopidogrel hydrogen sulfate group (Fig. 1).
Apart from differences in chemical structure of clopidogrel,
here was no variation in the methodology, type of instruments,
eagents, or laboratory staff.
We are aware that several determinants might play a role in
enerating these results, independently of the inhibitory effect of
he drug (6). In our group of patients, no significant differences
ere found in the prevalence of the cardiovascular risk factors in
elation to the different molecules of clopidogrel administered.
urthermore, the clinical presentation of ACS (i.e., STEMI vs.
STEMI patients) was similar in the different periods examined. In
ddition, the procedures of the catheterization laboratories and the
ardiologists were the same. Furthermore, no modification was made
Figure 1 HPR by ADP According tothe Type of Clopidogrel Administered
High platelet reactivity (HPR) by adenosine diphosphate (ADP) (defined as
10 mol/l ADP-induced platelet aggregation 70%). Clopidogrel hydrogen sul-
fate (open bars), clopidogrel base (solid bars).
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February 5, 2013:594–7in the organization of the reperfusion strategy of ACS in our city,
from the first aid to the emergency department and the catheteriza-
tion laboratory. In other words, we were not able to recognize, apart
from the change in the molecule of clopidogrel, a significant variation
in the clinical characteristics of patients or in the interventional
procedures, which accounts for the higher prevalence of HPR.
We emphasize that this finding only represents the descriptive
analysis of laboratory data produced in our department in relation to
the shift to the new preparation of clopidogrel and cannot be applied
to the several other generic forms of clopidogrel now available.
A specific ad hoc study implying the randomization to the 2
different formulations of clopidogrel is needed to definitely
prove the different effects on platelets. Present data emphasize
the need for accurate post-marketing surveillance of generic
forms of a drug such as clopidogrel for which the lack of
effective platelet inhibition is associated with a documented
increased ischemic risk.
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Letters to the Editor
Lack of Stroke Subtype
Information May Hinder Indirect
Comparison Between the
ROCKET-AF and Other Trials
of New Oral Anticoagulants
Although we agree with Lip et al. (1) on the limitation of their
study, we argue that lack of stroke subtype information may hinder
scientific conclusion by including the ROCKET-AF (Rivaroxaban
Once Daily Oral Direct Factor Xa Inhibition Compared With
Vitamin K Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation) in any indirect comparison of new oral
anticoagulants (NOA).
Several studies on indirect comparison among NOA in atrial
fibrillation (AF) patients reported slightly different results (1–3).
However, none of these studies took into account the distribution
of stroke subtypes as a confounder against indirect comparison
methods. To address the lack of comparability on high-risk
patients among trial populations, Schneeweiss et al. (3) conducted
a subgroup analysis in patients with a CHADS2 (congestive heart
failure; hypertension: blood pressure consistently above 140/90
mm Hg [or treated hypertension on medication]; age 75 years;
diabetes mellitus; prior stroke, transient ischemic attack [TIA], or
thromboembolism) score 3 and got similar results as those
reported by Lip et al. Nevertheless, this may not balance the
contribution of etiology of stroke or TIA to the treatment effects in
ROCKET-AF and other trials. In the study by Mantha et al. (2), all
stroke or TIA events were even considered as embolic episodes.
That strokes occur in patients with AF does not necessarily
point to an embolic etiology. In the normal population, roughly
20% of all TIA and ischemic strokes have a cardiac origin—most
commonly AF. Recent antithrombotic trials in AF patients vary in
the proportion of patients who had a previous TIA or stroke, with
a range between 14% and 24% (4). Approximately 60% to 70% of
first recurrent strokes have the same mechanism as the index stroke
(5). As a result, noncardioembolic strokes are the majority of the
recurrent strokes, and they might not benefit from NOA. In
ROCKET-AF, 52% of the patients experienced a stroke or TIA
before study entry. Unfortunately, no information of subtype was
reported in such trial with a large proportion of patients with
ischemic cerebral events (6). The treatment effects of NOA may be
diluted in ROCKET-AF by this, which may prevent it from being
compared with other trials of NOA.
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